FibroBiologics wants engineered cells to produce GLP-1 and other therapeutic peptides inside the body, potentially replacing repeated injections. But researchers have explored the idea for years, raising questions about what is new and how the technology would be controlled.
TL;DR
FibroBiologics wants to turn engineered cells into miniature factories that continuously produce GLP-1 and other therapeutic peptides inside the body. The approach could reduce the need for repeated injections, but earlier researchers have already demonstrated important parts of the concept. The questions now are what FibroBiologics has developed, how well it works and whether peptide production could be safely controlled once treatment begins.
On 7 October 2026, Houston-based biotechnology company FibroBiologics announced that it had filed a US patent application for technology designed to produce GLP-1, GIP, GLP-2 and other therapeutic peptides inside the body.
Instead of making a medicine in a factory and administering it repeatedly, the company proposes using genetically engineered cells to make the medicine directly inside the patient.
These cells would be grouped into small, three-dimensional structures called spheroids or organoids. Once administered, they could potentially keep producing therapeutic peptides over an extended period.
FibroBiologics also describes possible safety features, including devices that could be removed and genetic mechanisms designed to destroy the cells when treatment needs to stop.
The concept is interesting, particularly as pharmaceutical companies compete to develop longer-lasting obesity and diabetes treatments. However, using living cells to produce GLP-1 isn’t a new idea. Researchers were demonstrating versions of this approach more than fifteen years ago.
What remains to be established is whether FibroBiologics has developed a better way of doing it.
How would it work?
Most peptide medicines are manufactured outside the body, purified, tested and supplied in measured doses.
FibroBiologics proposes something different. It would genetically engineer living cells to produce therapeutic peptides and administer those cells to a patient. The cells could then act as a continuing source of treatment, potentially reducing the need for regular injections.
The proposed platform includes GLP-1 and GIP, hormones involved in blood-sugar regulation and appetite, as well as GLP-2, which is involved in intestinal function.
The company also describes the possibility of producing several peptides together, with different combinations selected for particular medical conditions. There’s an important distinction here. Producing GLP-1 inside the body isn’t the same as producing semaglutide or tirzepatide. Those medicines have been specifically engineered to behave differently from naturally occurring hormones.
A working treatment would need to produce the intended active molecules in sufficient quantities and maintain an appropriate level in the body.
FibroBiologics has described how its system might achieve this, but its 7 October announcement didn’t include measurements of peptide production, animal weight-loss results or evidence showing how long the proposed treatment could work.
Researchers have been doing this for years
The idea of using living cells to manufacture GLP-1 inside the body has a substantial research history.
In 2011, scientists demonstrated that genetically engineered cells could produce GLP-1 in response to light. The cells were implanted into diabetic mice, where the controlled production improved blood-sugar regulation.
Other researchers developed small capsules containing GLP-1-producing cells. One example was CellMed’s CellBeads technology, which was investigated as a way of delivering GLP-1 to the brain following serious neurological injury.
The programme progressed into a small human study involving 11 participants. The study was eventually terminated because the sponsor concluded that the treatment needed further improvement.
Although the research concerned brain injury rather than obesity, it demonstrated that living GLP-1-producing cells had already been investigated in humans.
In 2017, another research team developed genetically engineered skin grafts capable of producing a modified GLP-1-based molecule. The researchers could regulate production using doxycycline, an antibiotic that activated the engineered system. Experiments in mice showed improvements in blood-sugar regulation and resistance to diet-related metabolic problems.
These studies established that cells could be engineered to produce therapeutic hormones, placed into living organisms and, in some cases, controlled after implantation. The challenge has been turning those experimental systems into treatments that work reliably over long periods.
Other companies are already working on it
FibroBiologics is entering a field where several companies and research groups are pursuing similar goals through different methods.
Fractyl Health: Making the pancreas produce GLP-1
Fractyl Health is developing a gene therapy called Rejuva, which aims to make cells in the pancreas produce GLP-1. Rather than implanting specially prepared cells, Fractyl delivers genetic instructions to cells already inside the patient’s body. The company hopes this could provide long-lasting hormone production that responds to the body’s needs.
In May 2026, Fractyl announced that it had received authorisation in the Netherlands to begin a first-in-human study of its RJVA-001 treatment for type 2 diabetes. It’s also reported early animal results involving a treatment designed to activate both GLP-1 and GIP pathways.
Fractyl’s method is different from FibroBiologics’ proposed cell implants, but both aim to reduce the need for repeated treatment.
RenBio: Turning muscle into a medicine factory
RenBio is developing a system called MYO, which delivers genetic instructions into muscle cells. Those cells can then produce therapeutic substances over an extended period. In research published in 2026, RenBio demonstrated prolonged production of experimental GLP-1-related treatments in mice.
The company reported weight-loss and blood-sugar benefits lasting up to a year after a single administration, although results varied according to the experimental treatment and the animals’ diets.
The research provides evidence that long-lasting production is possible in animals. Whether the same approach would work safely and effectively in humans remains to be established.
An implantable living pharmacy
Researchers from Northwestern University, Rice University and Carnegie Mellon University have developed another approach. Their device, known as HOBIT, contains engineered cells capable of producing several therapeutic substances, including a GLP-1-like peptide.
One of the major difficulties with living-cell implants is keeping the cells alive. They need oxygen and nutrients, and cells buried too deeply inside an implant may struggle to survive. HOBIT includes a system that supplies oxygen to the implanted cells.
In rat experiments lasting approximately a month, the device maintained production of several therapeutic substances. Around 65% of the cells remained alive in oxygen-supported devices, compared with approximately 20% in devices without that support.
The research demonstrates a potential solution to one of the biggest problems facing living-cell treatments. Taken together, these projects show that producing medicines inside the body is already an active area of research. The different approaches have advantages and limitations, and none of the results establishes that FibroBiologics’ particular system will work.
What has FibroBiologics already developed?
FibroBiologics has previous experience combining different types of cells into three-dimensional structures.
In March 2025, a US patent application, US20250090595A1, was published describing structures containing fibroblasts and insulin-producing pancreatic cells. Laboratory experiments showed that these structures could produce insulin in response to glucose. Some experiments also examined insulin production after the structures were exposed to rat blood in a laboratory tube.
That is relevant experience, but it’s different from demonstrating that cells can produce GLP-1 continuously inside a living patient.
The company’s October announcement may represent an extension of this earlier research. However, the announcement didn’t provide the new patent application’s number, full claims or detailed experimental results.
Those details are important because the broader concept of engineered cells producing therapeutic hormones already exists. FibroBiologics may have developed something new in the way the cells are engineered, combined, protected or controlled. Examining the actual patent application would help establish what distinguishes its proposal from earlier work.
What happens when you need to stop treatment?
One of the most important questions concerns control.
With a conventional injection, doctors know how much medicine has been administered. They can reduce or stop future doses, even though the drug already in the body takes time to disappear.
Living cells are different. An implanted treatment could continue producing peptides for weeks, months or potentially longer. The amount produced might change as cells survive, die or respond to conditions inside the body. A patient’s treatment requirements could also change.
That makes it important to establish how production could be reduced or stopped. FibroBiologics describes two possible safeguards.
The first is a genetic safety mechanism that could be activated to destroy the engineered cells.
The second is placing the cells inside a device that could be removed if treatment needed to end.
Both approaches have been studied previously. In 2011, researchers demonstrated a genetic safety system that removed more than 90% of specially engineered immune cells within 30 minutes after an activating treatment was administered. Later studies found that the effectiveness of similar systems depended partly on how the genetic safety mechanism was introduced into the cells.
A 2022 study showed that using a more robust genetic design could substantially improve the reliability of cell elimination. This is encouraging research, but each system needs to be tested in the actual cells intended for treatment.
FibroBiologics has described potential ways of stopping production. Its announcement has not yet provided experimental evidence showing how quickly or reliably those safeguards work in its proposed GLP-1-producing cells.
That leaves several questions. Could doctors reduce production without removing the entire treatment? Would an implanted device be completely retrievable? How quickly would peptide levels fall after the cells were destroyed or removed?
These are practical questions that would need to be answered before the technology could be considered for routine clinical use.
Manufacturing living medicines
Another challenge is producing the same treatment consistently. Traditional peptide medicines are manufactured in batches. Manufacturers test the finished material before it reaches patients, checking its identity, quantity, purity and other quality requirements. A living-cell treatment needs similar quality controls, but also requires cells that remain healthy and behave consistently after administration.
FibroBiologics already has experience developing cellular therapies, including CYWC628, an experimental treatment for diabetic foot ulcers.
Its July 2026 financial and operational update described ongoing manufacturing work and the completion of three CYWC628 production batches. Two had been released, while the third was awaiting required testing. These activities relate to its wound-care treatment rather than the proposed GLP-1 technology, but they illustrate the work involved in preparing living-cell products for clinical development.
For the new peptide platform, the company would need to show that it can manufacture cells consistently and that those cells continue producing appropriate quantities of the intended peptides after administration.
Can the company fund its development?
FibroBiologics is developing several treatments, including programmes for diabetic foot ulcers, psoriasis and multiple sclerosis. Its financial position is relevant because turning a laboratory concept into an approved treatment requires substantial investment. According to its financial filing for the quarter ending 30 June 2026, FibroBiologics held approximately $3.5 million in cash and had used approximately $7.7 million in operating activities during the first six months of the year.
The filing raised concerns about its ability to continue operating without additional funding. The company has also undertaken financing activities. Its second-quarter announcement described a $3 million public offering and a private placement providing $3 million upfront, with the possibility of additional proceeds if warrants are exercised. Some of that funding may already have been included in the June cash figures.
In September, chief scientific officer Hamid Khoja also completed an investment of approximately $500,000. These figures don’t establish the company’s present cash balance, but they show why future funding will be important.
FibroBiologics hasn’t announced a dedicated development budget, selected clinical candidate or human-trial timetable for the new GLP-1 platform.
A different kind of peptide manufacturing
There is an interesting connection to another technology I covered in September. Virtu Pharmako has been developing a bacterial fermentation process intended to manufacture semaglutide-related peptide material more efficiently.
The two approaches both use biological systems to produce peptide-related substances, but the objectives are different.
Virtu’s approach uses engineered bacteria in industrial manufacturing facilities. The resulting material can be processed, purified and tested before it becomes part of a finished medicine.
FibroBiologics proposes leaving the drug-producing cells inside the patient.
One approach aims to make peptide manufacturing more efficient. The other aims to change how patients receive treatment. That difference also creates new questions about controlling production once the cells are inside the body.
What happens next?
FibroBiologics has announced an interesting proposal in an area of research that has been developing for more than fifteen years.
Earlier studies have already demonstrated living GLP-1-producing cells, engineered skin grafts, long-lasting hormone production and implantable systems designed to keep therapeutic cells alive.
FibroBiologics has its own experience developing cellular structures, and its latest patent application may contain an approach that builds on this work.
The next important step is demonstrating how that approach performs. Researchers would need to establish how much biologically active peptide the cells produce, how long production continues, what effects the treatment has and how reliably it can be controlled.
Long-term safety, manufacturing consistency and the ability to stop treatment would also need to be investigated.
The company’s patent application may eventually clarify which features it considers new, while experimental results would help establish whether those features improve on earlier technologies.
The appeal of a living GLP-1 factory is straightforward: a treatment that keeps producing medicine without repeated injections. The challenge is making that production reliable, effective and controllable.
FibroBiologics has presented its vision. The scientific work that would establish its clinical potential still lies ahead.
Comments